Ekholm E, Rantanen V, Antila K, Salminen E
Department of Obstetrics and Gynaecology, University of Turku, Finland.
Eur J Cancer. 1997 Aug;33(9):1419-24. doi: 10.1016/s0959-8049(97)00044-0.
Paclitaxel has become part of standard therapy in the treatment of ovarian and breast cancer. Concern has been raised about the effects of paclitaxel on cardiovascular function. Therefore, this study of the effects of paclitaxel on autonomic cardiovascular control was initiated. Eighteen women treated for ovarian or breast cancer were examined with autonomic cardiovascular function tests, once before the treatment and once after the second course of paclitaxel. Heart rate and blood pressure variability and changes in heart rate and blood pressure responses to the tests were measured. Baroreflex sensitivity was calculated from the Valsalva manoeuvre non-invasively. Paclitaxel did not change heart rate variability at rest compared with the pretreatment level. However, medium frequency variability of blood pressure was smaller after treatment with paclitaxel. Paclitaxel treatment did not impair the heart rate and blood pressure responses to the autonomic function tests. The results do imply that paclitaxel alters sympathetic control of blood pressure. Nevertheless, paclitaxel does not appear to precipitate autonomic cardiac neuropathy.
紫杉醇已成为卵巢癌和乳腺癌标准治疗方案的一部分。人们对紫杉醇对心血管功能的影响表示担忧。因此，启动了这项关于紫杉醇对自主心血管控制影响的研究。对18名接受卵巢癌或乳腺癌治疗的女性进行了自主心血管功能测试，一次在治疗前，一次在紫杉醇第二疗程后。测量了心率和血压变异性以及测试期间心率和血压反应的变化。通过瓦尔萨尔瓦动作无创计算压力反射敏感性。与治疗前水平相比，紫杉醇在静息状态下并未改变心率变异性。然而，紫杉醇治疗后血压的中频变异性较小。紫杉醇治疗并未损害自主功能测试中的心率和血压反应。结果确实表明紫杉醇改变了对血压的交感神经控制。尽管如此，紫杉醇似乎不会引发自主神经性心脏病。
